NCT04660760View on ClinicalTrials.gov

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

May 31, 2026

Conditions
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Unresectable Gastric AdenocarcinomaLocally Advanced Unresectable Gastroesophageal Junction AdenocarcinomaMetastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaPathologic Stage III Gastric Cancer AJCC v8Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Gastric Cancer AJCC v8Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIB Gastric Cancer AJCC v8Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIC Gastric Cancer AJCC v8Pathologic Stage IV Gastric Cancer AJCC v8Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
DRUG

Paclitaxel

Given IV

OTHER

Quality-of-Life Assessment

Complete questionnaires

BIOLOGICAL

Ramucirumab

Given IV

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (15)

30322

WITHDRAWN

Emory University Hospital/Winship Cancer Institute, Atlanta

33331

RECRUITING

Cleveland Clinic-Weston, Weston

35233

NOT_YET_RECRUITING

University of Alabama at Birmingham Cancer Center, Birmingham

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

52242

NOT_YET_RECRUITING

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53226

WITHDRAWN

Aurora Cancer Care-Milwaukee West, Wauwatosa

54301

RECRUITING

Saint Vincent Hospital Cancer Center Green Bay, Green Bay

55416

COMPLETED

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

61801

WITHDRAWN

Carle Cancer Center NCI Community Oncology Research Program, Urbana

67214

WITHDRAWN

Cancer Center of Kansas - Wichita, Wichita

68198

WITHDRAWN

University of Nebraska Medical Center, Omaha

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

85715

WITHDRAWN

Arizona Clinical Research Center, Tucson

90033

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER